Published in TB and Outbreaks Week, February 7th, 2006
The Phase II trial results of a gatifloxacin-containing regimen are demonstrating good potential. The regimen is significantly more potent than the currently recommended 6-month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol, and suggests that when gatifloxacin is used instead of ethambutol, the standard 6-month regimen may be shortened to 4 months.
"We are working to bring...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week